Ibogaine: What the Evidence Shows
Ibogaine treatment risks start with the heart. The Schedule I psychedelic now fast-tracked by the White House and funded by Texas can stop a healthy heart days after a dose, has never passed a randomized controlled trial for addiction, and is sold at $5,000 to $20,000 a stay in unregulated clinics abroad. The government’s own top drug scientist said it would be “dead in the water” at the FDA. Here is the record, every figure sourced.
Executive Order 14401 names ibogaine for a Right to Try pathway. No phase 3 trial exists, and the FDA says there are “serious safety concerns.”
A drug that can kill, with the thinnest evidence and the biggest political push
Ibogaine is a psychoactive alkaloid from the root bark of the iboga shrub of Gabon and Congo, used in Bwiti ceremonies and, since the 1960s, promoted as a one-dose cure for addiction. It is listed in Schedule I at 21 CFR 1308.11. Its active metabolite, noribogaine, stays in the body for days.
The government’s own scientist
“I went to Transcend because I was concerned, actually, about pretty severe QT prolongation with ibogaine.”
Nora Volkow, Director, National Institute on Drug Abuse, May 2026
In July 2025 Dr. Volkow told PBS that ibogaine “would be dead in the water” for FDA approval because of its cardiotoxicity. Nine months later the White House put it on a fast track. Nothing changed but the politics.
The FDA, October 2026
“With ibogaine, there are important scientific questions as well as serious safety concerns.”
Michael Davis, Director, FDA Center for Drug Evaluation and Research, FDA press release, October 5, 2026
The agency’s request for public input asks how to monitor “cardiac and neurologic adverse events” and proposes a starting dose “not exceeding 10 mg/kg,” the dose at which half the patients in the Dutch study crossed the QTc danger line.
FDPS is not against studying ibogaine. If a synthetic analog without the cardiac liability can pass real trials, the FDA should approve it. What FDPS opposes is the campaign to bypass that process: state appropriations, Right to Try end runs, opioid settlement money and a presidential order built on a podcast conversation and a 30-person study with no control group. The full position is in Psychedelics policy: science first, no shortcuts.
How ibogaine stops a heart
Ibogaine and noribogaine block the hERG potassium channel that resets the heart between beats. That lengthens the QT interval and can trigger torsades de pointes, a fatal arrhythmia. Because noribogaine lingers for days, the danger outlasts the trip.
QTc prolongation at a standard dose
14 opioid-dependent patients, 10 mg/kg, Dutch university hospital
A QTc above 500 milliseconds is the threshold at which cardiologists stop drugs. “Severe transient ataxia with inability to walk without support was seen in all patients.”
Deaths on the record
Victims were 24 to 54 years old and died 1.5 to 76 hours after taking the drug. Litjens and Brunt presented eight cases of ventricular arrhythmia and QT prolongation “in individuals without any pre-existing cardiovascular condition or family history,” and concluded: “With limited medical supervision, these are risky experiments and more ibogaine-related deaths are likely to occur.”
Alper, Stajić and Gill, J Forensic Sci, 2012; Litjens and Brunt, Clinical Toxicology, 2016; Corkery, Prog Brain Res, 2018
No pre-existing condition required
A 2026 commentary in Addiction: case reports “demonstrate that these events occur with therapeutic doses of ibogaine and in individuals without pre-existing cardiac conditions.” Screening cannot find a risk factor that is not there.
Brunt, Addiction, 2026; Alper et al., hERG blockade, Cardiovasc Toxicol, 2016
What the poison service sees
Seven ibogaine patients reached a UK poisons service between 2012 and 2022. All seven had neurological symptoms and six had cardiotoxicity, including cardiac arrest, torsades de pointes and QT prolongation.
Even the drug company saw it
In atai’s 2023 phase 1 trial, one healthy volunteer at 9 mg/kg showed a QTcF prolongation of 90 to 94 milliseconds, reaching 493 to 501 milliseconds. That is a company trying to get the drug approved, reporting the signal in its own volunteers.
atai Life Sciences results, August 2023; Koenig and Hilber, Molecules, 2015
Beyond the heart
A 2022 systematic review of human adverse events found acute effects including tachycardia, hypotension, seizures, anoxic brain injury, ataxia and unconsciousness, and prolonged effects including insomnia, delusions, aggressiveness, dissociation and amnesia, with most evidence from case reports and uncontrolled settings. Hallucinogen persisting perception disorder has been reported after ibogaine. And a Colorado man was sentenced to four years in prison, and a South African clinic operator convicted of culpable homicide, after giving ibogaine to people who then died.
Ona et al., Psychopharmacology, 2022; FDPS ibogaine white paper, 2026
Study by study, the case for ibogaine is anecdote
Every study that advocates cite is small, uncontrolled, self-selected, run abroad, or funded by people with a stake in the result. Often all five.
| Study | Design | Result | What to know |
|---|---|---|---|
| Noller et al., 2018 (New Zealand) | 14 opioid-dependent patients, observational | 8 completed all follow-ups | “One patient enrolled in the study died during treatment.” |
| Brown and Alper, 2018 (Mexico) | 30 patients, open label, no control | 50 percent opioid-free at 1 month; the effect faded after | The authors: “There are no published prospective studies of drug use outcomes with ibogaine.” Rolling Stone’s summary: 7 of 30 reported no recent opioid use a year later. |
| Davis et al., 2017 (survey) | 88 people treated in Mexico, online survey | 30 percent said they never used opioids again | “70% of the total sample reported a relapse following treatment.” MAPS-funded; a MAPS employee among the authors. |
| Mash et al., 2018 | 191 patients, open-label case series | Withdrawal symptoms eased | The authors: benefits “are based on anecdotal reports from a small series of case reports that used retrospective recruitment procedures.” |
| Cherian et al., Nature Medicine, 2024 (Stanford) | 30 male special-operations veterans, no control group, dosed at Ambio in Mexico | Improvement in PTSD, depression and function at one month | Stanford “played no role in ibogaine administration.” Participants also got sweat lodge, massage, yoga, reiki, breathwork and coaching. The authors: the contribution of those, “international travel, expectancy or other nonspecific effects, cannot be determined.” Two authors hold a patent application; one founded an ibogaine supply company. |
| 12-month follow-up, 2026 | 25 of the 30 veterans | Benefits reported to persist | “Most participants reported using other psychedelic substances or pursuing other interventions during the follow-up period.” |
The verdict of the reviews
“No double-blind RCT to date has demonstrated that ibogaine or noribogaine can effectively treat opioid use disorder. … current evidence is insufficient to support its clinical use.”
Kervadec et al., Journal of Clinical Psychopharmacology, 2026
The risk advocates do not mention
“’Detoxification’ from methadone or buprenorphine in favor of an as-yet unproven therapy like ibogaine could result in an increased risk of opioid overdose for some.”
Terasaki, Sackett and Monte, Journal of Addiction Medicine, 2026
Methadone and buprenorphine are the treatments with the strongest evidence for keeping people with opioid addiction alive. The ibogaine pitch asks patients to stop them.
This is the pattern across the field: a review of 193 psilocybin studies found it “rife with conflicts of interest,” and across 11 recent psychedelic trials a median of 39 percent of participants had used the drug before. The people who profit if ibogaine is approved are the people writing the evidence that says it works. See Is psilocybin safe? and what the FDA found on MDMA for the same problem in the drugs furthest along.
From a podcast to $50 million to the Oval Office
Only 12 percent of Americans had heard of ibogaine in a 2023 UC Berkeley survey, against 96 percent for LSD. That obscurity is the opening: the industry gets to define the drug before anyone hears about the deaths.
- January 2025Former Texas Governor Rick Perry and W. Bryan Hubbard of Americans for Ibogaine pitch the drug on The Joe Rogan Experience. Perry, at SXSW 2026: “The veteran population is a very sellable population to go to the legislature with.” Spectrum News
- June 11, 2025Texas signs SB 2308: $50 million in state matching funds for an FDA ibogaine trial. Governor’s office
- March 2026The Texas Tribune reports the state “couldn’t find a company” willing to match the $50 million, so Texas will run its own program. Rice University’s Katharine Neill Harris: a drug development effort “will likely require much more than $100 million overall.” Texas Tribune
- April 18, 2026Executive Order 14401 names “ibogaine compounds” for a Right to Try pathway, priority vouchers and $50 million in federal funds for state programs. The President described a text from Joe Rogan as the spark. White House
- April 2026Kentucky passes SB 77 over the governor’s veto after stripping its $21 million a year appropriation. Gov. Beshear’s veto message: “The bill picks one treatment and one drug … This raises the concern that this legislation is meant to pay a specific company.” Veto message; bill history
- June 30, 2026Rep. Morgan Luttrell introduces H.R. 9559, the IBOGAINE Act. Congress.gov
The Kentucky warning
In 2023 Kentucky’s opioid settlement commission, led by Hubbard, proposed spending $42 million of money meant for opioid victims on ibogaine. Cardiologist Mark Haigney told the commission: “My opinion is that ibogaine is not safe. The efficacy is unproven.” A new attorney general dropped the plan.
The funders
Americans for Ibogaine, Veterans Exploring Treatment Solutions, Reason for Hope and the New Approach PAC that ran Colorado’s Proposition 122 share members of the Psychedelic Science Funders Collaborative, whose 2025 roadmap calls for “groundwork” on ibogaine and names veterans as one of the most sympathetic groups in the country for creating urgency. Arizona added $5 million in its 2026 budget.
FDPS ibogaine white paper, 2026; Reason Foundation on Arizona HB 2871
That is Hubbard’s claim at SXSW in March 2026. No controlled human trial has shown it. The only mechanism established beyond doubt in humans is hERG blockade, the one that stops hearts.
Some do, and they deserve real trials, not experiments abroad. The 30-veteran Stanford study had no control group, and its own authors could not separate the drug from the travel, the group, the coaching and the expectation. The funders’ own strategy document calls veterans the messenger. They were chosen.
Where Americans actually get ibogaine
Because it is illegal to prescribe in the United States, the market is in Mexico and Costa Rica, where it is unregulated and where no one counts the casualties.
clinics and wellness centers offering ibogaine in Mexico found by The New York Times in 2026, up from almost none a decade ago. “There is no official tally of injuries, deaths and adverse experiences.” Treatments run “from $5,000 to nearly $20,000, not including travel.”
of 49 psychedelic retreats surveyed employed any medical professional, and about one in ten had a staff member with emergency medical training, in a JAMA Network Open study that found “substantial variability in the implementation of safety precautions.”
is the mortality rate “in untrained hands” estimated by Jeffrey Kamlet, the chief medical officer of one of the largest ibogaine clinics, who told Rolling Stone he keeps “a folder of over 60 ibogaine deaths.” Kenneth Alper, the field’s leading researcher: “I’m not so sure that this can be done widely without compromising.”
Deaths the industry reported itself
A 49-year-old New Yorker died in May 2024 at a Cancún clinic eleven days after arriving and two days after his ibogaine session; no autopsy was performed. A 40-year-old New Mexico social worker died of a heart attack at a Costa Rica retreat in August 2024, in a country where ibogaine is illegal. In January 2026 Ambio, the Mexico clinic that hosted the Stanford study, announced that a patient had died in its detox program and acknowledged “ongoing risks associated with ibogaine.” The clinic world also carries a four-year prison sentence in Colorado, a culpable homicide conviction in South Africa, and documented sexual abuse of impaired patients.
Rolling Stone; Tico Times, 2025; Ambio Life Sciences, January 2026; FDPS ibogaine white paper, 2026
Ibogaine treatment risks: common questions
What are the risks of ibogaine treatment?
The main risk is sudden cardiac death. Ibogaine and its metabolite noribogaine block the hERG potassium channel, prolonging the heart’s QT interval; in a Dutch hospital study half of patients at a standard dose crossed the 500-millisecond danger line. At least 33 deaths were on record by 2018, many in people with no heart condition, occurring up to 76 hours after the dose. Seizures, ataxia, brain injury, psychosis, lasting perceptual disturbance and overdose after stopping methadone or buprenorphine are also documented.
Does ibogaine cure addiction?
No study has shown that. As of 2026 no double-blind randomized controlled trial has demonstrated that ibogaine treats opioid use disorder, and the published evidence consists of small open-label series, surveys and one 30-person uncontrolled veterans study run in Mexico. In the best-known Mexico series, half of patients were opioid-free at one month and the effect faded afterward; in a survey of 88 patients, 70 percent relapsed.
Is ibogaine legal in the United States?
No. Ibogaine is a Schedule I controlled substance under 21 CFR 1308.11, with no FDA-approved use, and U.S. doctors cannot prescribe it. Executive Order 14401 of April 2026 directs the FDA and DEA to create a Right to Try pathway for ibogaine, and Texas, Arizona and Kentucky have passed laws to fund research, but none of that makes it legal to sell or prescribe.
Is ibogaine legal in Mexico?
Ibogaine is unregulated in Mexico, which is why more than 40 clinics operate there, mostly for American clients paying $5,000 to nearly $20,000. There is no official count of injuries or deaths. It is illegal in Costa Rica, where a retreat death occurred in 2024.
What did the Stanford ibogaine study find?
The 2024 Nature Medicine study followed 30 male special-operations veterans who paid to be treated at a clinic in Mexico and reported large improvements in PTSD, depression and function a month later. It had no control group, Stanford did not administer the drug, participants also received sweat lodge, massage, yoga, reiki and coaching, and the authors said the contribution of those elements and of expectation “cannot be determined.” Two authors hold a related patent application.
What does FDPS want?
Rigorous, independent, controlled trials through the FDA, with the cardiac monitoring the agency itself says is needed; no state appropriations, opioid settlement diversions or Right to Try end runs that put an unproven cardiotoxic drug in front of desperate people; and public education so that veterans and families hear about the risks before the marketing reaches them.
Related: Psychedelics hub · The psychedelic hype vs. the evidence · Who opposes psychedelic legalization · Is psilocybin safe? · MDMA therapy: what the FDA found · Arguments against psychedelic legalization · Drug facts · The Drug Report on psychedelics
Science, not celebrity, should decide what counts as medicine.
Veterans and people fighting addiction deserve treatments that have been proven, not experiments sold to them abroad. Read the FDPS position and help keep the evidence ahead of the lobbying.
